What is Variational AI?
We discover novel drug-like small molecules with optimized properties for defined targets
How to use Variational AI?
Expand your imagination in 4 easy steps: define your target product profile (TPP), select your on-target(s), off-target(s), and other properties, and Enki does the rest!
Variational AI's Core Features
Generative AI algorithms
Ensemble of trained models
Decades worth of experimental data
Variational AI's Use Cases
Discover new therapeutics
Drug discovery and development
- Variational AI Support Email & Customer service contact & Refund contact etc.
Here is the Variational AI support email for customer service: [email protected] . More Contact, visit the contact us page(https://variational.ai/#contact)
Variational AI Company
Variational AI Company name: Variational AI Inc. .
Variational AI Company address: 577 Great Northern Way, #240 Vancouver, BC V5T 1E1 Canada.
More about Variational AI, Please visit the about us page(https://variational.ai/#company).
Variational AI Linkedin
Variational AI Linkedin Link: https://ca.linkedin.com/company/variational-ai
Variational AI Twitter
Variational AI Twitter Link: https://twitter.com/intent/follow?screen_name=VariationalAI
FAQ from Variational AI
What is Variational AI?
We discover novel drug-like small molecules with optimized properties for defined targets
How to use Variational AI?
Expand your imagination in 4 easy steps: define your target product profile (TPP), select your on-target(s), off-target(s), and other properties, and Enki does the rest!
What is Enki?
Enki is a generative AI platform for drug discovery.
How does Enki work?
Enki uses generative algorithms trained on decades worth of experimental data to generate novel small molecule structures.
What is a target product profile?
A target product profile (TPP) is a series of prompts used to describe the molecules in the language of chemistry.
Can Enki generate structures that meet the TPP?
Yes, Enki can rapidly generate structures that meet the TPP.
Is Enki accessible for early access?
Yes, early access is available for about 100 kinase targets to start.